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Abstract
BACKGROUND: Borderline ovarian tumor (BOT) is an epithelial ovarian tumor with atypical epithelial proliferation 
without stromal invasion. BOTs may have an aggressive fashion with associated microinvasion feature, peritoneal 
“implants,” regional lymphadenopathy, and higher International Federation of Gynecology and Obstetrics (FIGO) 
stage. CD133 is cancer stem cells (CSCs) marker that promotes cell proliferation and tumor invasion through 
induction of nuclear factor kappa B and upregulation of MMP9. Aldehyde dehydrogenase 1A1 (ALDH1A1) is CSCs 
marker that promotes cell proliferation through the upregulation of c-MYC and cyclin-D1. 
AIM: The aim of this study was to investigate the correlation between CD133 and ALDH1A1 expression with FIGO 
stage. This research was performed as an analytic-observational with a cross-sectional design. 
METHODS: This research using a paraffin block of patients diagnosed as BOT in Hasan Sadikin Hospital 
Bandung. Samples were divided in two groups: FIGO stage IA and FIGO stage >IA. All samples were stained by 
immunohistochemistry CD133 and ALDH1A1. All data were analyzed using the Chi-square test with a significant 
level 5%. 
RESULTS: This study showed a statistically significant correlation between CD133 (p = 0.047) and ALDH1A1 (p = 
0.042) expression with FIGO stage in BOT. Multivariate analysis showed there was no correlation between CD133 
and ALDH1A1 in the affected of FIGO stage in BOT. 
CONCLUSION: CD133 and ALDH1A1 in BOT can be considered as a factor to predict the prognosis of BOT through 
predict FIGO stage.
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Introduction
Epithelial ovarian tumor (EOT) consists 
of benign EOT (cystadenoma), malignant EOT 
(carcinoma), and borderline ovarian tumor (BOT) [1]. 
Characteristics of BOTs are atypical epithelial 
proliferation and without stromal invasion [1], [2], [3]. 
BOTs comprise up to 15–20% of ovarian epithelial 
neoplasms. BOTs often occurred in younger women 
with an average age is 40 years old [2]. According to 
the WHO classification, BOT consists of serous BOT, 
mucinous BOT, endometrioid BOT, and borderline 
Brenner tumor [1]. BOT often occurred at an earlier 
stage and has a better prognosis than malignant 
ovarian tumors. Some BOTs may have an aggressive 
fashion with associated peritoneal “implants,” 
regional lymphadenopathy, and higher International 
Federation of Gynecology and Obstetrics (FIGO) 
stage [1], [4].
Cancer stem cells (CSCs) are a small 
proportion of tumor cells which are proposed to be able to 
proliferate and self-renew and invasion extensively [5]. 
CD133 and aldehyde dehydrogenase 1A1 (ALDH1A1) 
are CSC marker that can identify in ovarian tumor and 
correlate with a stage in ovarian cancer [6]. CD133 
promotes cell proliferation, tumorigenesis, and tumor 
invasion and metastasis through induction of nuclear 
factor kappa B and upregulation of MMP9 [7]. ALDH1A1 
promotes cell proliferation through upregulation of 
c-MYC and cycin-D1 [8]. High tumor cell proliferation, 
high ability of invasion, implants, and involvement of 
regional lymphadenopathy in BOT may influence FIGO 
stage and few cases of recurrences may occur [1]. 
Stage in BOT currently based on FIGO staging system. 
FIGO staging system according to involvement of tumor 
mass, whether unilateral or bilateral, tubal involvement, 
tumor mass in ascites fluid, peritoneal, lymph node 
involvement, or distant metastasis [9]. Loizzi et al. found 
that majority cases BOT had FIGO stage I (85.5%) and 
the remainder exhibited FIGO stage II (7.3%) and FIGO 
stage III (7.3%) [3].
To the best of our knowledge, no data 
have been reported until now about the role of the 
immunohistochemically assessed expression of CD133 
and ALDH1A1 of BOT in a large, single Institution series 
in Indonesia.
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Subjects and Methods
This study uses an analytic observational 
method with a cross-sectional study design and 
retrospective data retrieval/collection. Ethical clearance 
has been approved/assessed by Health Research 
Ethic Commission, Padjadjaran University, assessment 
number 1144/UN6.KEP/EC/2018. The inclusion criteria: 
The samples were obtained from patients registered 
at Hasan Sadikin Hospital, were diagnosed with BOT 
(serous BOT, mucinous BOT, endometrioid BOT, and 
borderline Brenner tumor) during January 2013 to July 
2018. All paraffin blocks from all samples were good 
and all samples have complete data about FIGO stage 
in the medical record.
All samples were classified as FIGO stage IA 
(unilateral involvement) and FIGO stage >IA (bilateral 
involvement or involvement to another organ). Analysis 
of expression: Samples from paraffin blocks were 
prepared for immunohistochemistry (IHC) analysis; 
IHC analysis was performed based on the protocol 
provided by the anatomical pathology laboratory. 
The slides were visualized under the microscope 
with three reviewers that have no knowledge about 
clinicopathologic data.
Histoscore calculation
The positive result was shown/visualized as 
brown staining on the tumor cell. Analysis on CD133 
was evaluated by brown staining in the cytoplasmic 
membrane of tumor cells and ALDH1A1 expression was 
evaluated by brown staining assessed in the cytoplasm. 
The stain intensity and distribution measured under the 
microscope was then converted into histoscore and 
categorized in high and low expression. This study used 
antibody CD133 (Polyclonal antibody, Elabscience) 
with dilution 1:200 and antibodyALDH1A1 (Polyclonal 
antibody, Santacruz) with dilution 1:800. The intensity 
was scored as having no expression (0), or weak 
(1), moderate (2), or strong (3) tumor-cell staining. 
Distribution was scored as having no expression (0), 
or <10% (1), 10–50% (2), or >50% of (3) tumor-cell 
staining.
Histoscores obtained from the samples 
were represented on a scale of 0–9. Histoscores 
were classifying to weak (histoscore ≤6) and strong 
(histoscore >6).
This research was performed as an analytic-
observational with a cross-sectional design. Statistical 
analysis was performed with SPSS using the Chi-
square test with a significant level 5%. p <0.05 was 
considered to be statistically significant and in the test 
of independence (multivariate analysis), a p >0.05 was 
considered to show independence between CD133 and 
ALDH1A1.
Results
During January 2013–July 2018, there were 
101 cases of BOT which were registered; however, 
only 84 samples were matched to inclusion criteria. 
Age ranging from 18 to 71 years (median 42 years) 
and 47 patients (56%) was over 40 years of age. The 
most common histopathology type was mucinous BOT 
in 59 patients (70.2%) and followed by serous BOT in 
22 patients (26.2%) (Table 1).
Table 1: Characteristic of research subject
Variable n=84 (%)
Age (year)
Mean±Std. 41.13±13.025
Median 42.00
Range (min–max) 18.00–71.00
<40 37 (44.0%)
≥40 47 (56.0%)
Type of histopathology 
Mucinous BOT 59 (70.2%)
Serous BOT 22 (26.2%)
Endometrioid BOT 2 (2.4%)
Borderline Brenner tumor 1 (1.2%)
Parity 
P0 15 (17.9%)
P≥1 69 (82.1%)
Characteristic of this research subject based on age, type of histopathology, and parity. BOT: Borderline 
ovarian tumor.
From this study, we found 66 patients with 
FIGO stage IA. Fourteen patients (21.2%) showed 
low expression of CD133 and 52 cases (78.8%) 
showed high expression of CD133 (Figure 1a). 
Moreover, 18 patients with FIGO stage more than 
IA showed low expression in 8 cases (44.4%) 
and high expression in 10 cases (55.6%). From 
statistical analysis showed the significant correlation 
between CD133 (p < 0.05) expression with FIGO 
stage in BOT. Expression of ALDH1A1 in FIGO 
stage IA showed low expression in 11 patients 
(16.7%) and high expression in 55 patients (83.3%) 
(Figure 1b). Patients with FIGO stage >IA showed 
low expression in 7 patients (38.9%) and high 
expression in 11 patients (61.1%). From statistical 
analysis showed the significant correlation between 
ALDH1A1 (p < 0.05) expression with FIGO stage in 
BOT (Table 2). Multivariate analysis showed there 
was no correlation between CD133 and ALDH1A1 in 
the affected of FIGO stage in BOT (Table 3).
Figure 1: CD133 and aldehyde dehydrogenase 1A1 (ALDH1A1) 
expression of borderline ovarian tumor in this study. (a) CD133 
strong expression in this study, tumor cell stained with CD133 
antibody in the cytoplasmic membrane (200×). (b) ALDH1A1 strong 
expression in this study, tumor cell stained with ALDH1A1 antibody 
in the cytoplasm (200×)
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Discussion
Prognostic factors in BOT include age, FIGO 
stage, residual disease following surgery, type of 
peritoneal implants (with or without invasion), presence 
of microinvasion, micropapillary pattern, and the CA-125 
value. Prognosis of BOT overall has a positive prognosis 
because over 80% of cases are diagnosed at an early stage 
of the disease and radical surgery and surgical staging are 
the standard of care for this disease includes hysterectomy, 
bilateral salpingo-oophorectomy, omentectomy, multiple 
biopsies, and peritoneal cytology [2].
Table 3: Multivariate analysis correlation CD133 and ALDH1A1 
expression with FIGO stage of BOT
Variable Estimation rate SE p value
CD133 -0.972 0.577 0.092
ALDH1A1
Constant 
-1.035
2.128
0.602
1.354
0.602
0.116
There is no correlation between CD133 and ALDH1A1 expression with FIGO stage. BOT: Borderline 
ovarian tumor, FIGO: International Federation of Gynecology and Obstetrics, ALDH1A1: Aldehyde 
dehydrogenase 1A1.
FIGO stage for ovarian carcinoma includes 
BOT which is the most superior staging system for 
predict patient prognosis through discriminating 
survival outcomes [10]. FIGO stage is according to 
the involvement of tumor mass, whether unilateral 
or bilateral, tubal involvement, tumor mass in ascites 
fluid, peritoneal, lymph node involvement, or distant 
metastasis [9]. The primary route of ovarian cancer 
expanding/metastasis includes intraperitoneal 
implantation of exfoliated tumor cells and spreading 
through retroperitoneal lymphatic channels [10].
CSCs are a small proportion of tumor cells 
which are proposed to be able to proliferate and self-
renew and invasion extensively [5]. CD133 is one of 
CSCs marker in ovarian cancer [6]. Long et al. found 
that the presence of CD133+ ovarian CSC can undergo 
an epithelial–mesenchymal transition-like process and 
display enhanced metastatic capacity of tumor cells 
in vitro and in vivo through secreting soluble mediators. 
CCL5 is chemokine which is one of the soluble mediators 
produced by CD133+ ovarian CSC. Signaling of CCL5 
is an important thing for the invasive capability of CSC 
and tumor cells [11].
This study performed CD133 expression 
analysis on FIGO stage and microinvasion feature of 
BOT. The result from IHC staining confirms that there 
are 55.6% of patients with FIGO stage more than IA 
showed high expression of CD133. From statistical 
analysis showed the significant correlation between 
CD133 (p < 0.047) expression with FIGO stage in BOT. 
High expression of CD133 results in high stage FIGO 
stage (FIGO stage more than IA).
ALDH1A1 is a marker of CSC that promotes 
self-renewal, differentiation, and self-protection of cells. 
High expressions of ALDH1A1 correlated with poor 
cancer prognosis but not correlate with highly malignant 
phenotypes [8]. Hence, in this study, we performed 
ALDH1A1 expression analysis on FIGO stage of BOT. 
The result from IHC staining confirms that there are 
61.1% of patients with FIGO stage more than IA showed 
high expression of ALDH1A1. From statistical analysis 
showed the significant correlation between ALDH1A1 
(p<0.042) expression with FIGO stage in BOT. High 
expression of ALDH1A1 results in high stage FIGO 
stage (FIGO stage more than IA).
This study also performed multivariate analysis 
correlation CD133 and ALDH1A1 expression with FIGO 
staging. There was no correlation between CD133 and 
ALDH1A1 expression with FIGO stage.
Conclusion
There was a significant correlation between 
CD133 with FIGO staging and correlation between 
ALDH1A1 with FIGO stage.
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